The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Abstract
NMDA receptor hypofunction could be involved, in addition to the positive, also to the negative symptoms and cognitive deficits found in schizophrenia patients. An increasing number of data has linked schizophrenia with neuroinflammatory conditions and glial cells, such as microglia and astrocytes, have been related to the pathogenesis of schizophrenia. Cannabidiol (CBD), a major non-psychotomimetic constituent of Cannabis sativa with anti-inflammatory and neuroprotective properties induces antipsychotic-like effects. The present study evaluated if repeated treatment with CBD (30 and 60 mg/kg) would attenuate the behavioral and glial changes observed in an animal model of schizophrenia based on the NMDA receptor hypofunction (chronic administration of MK-801, an NMDA receptor antagonist, for 28 days). The behavioral alterations were evaluated in the social interaction and novel object recognition (NOR) tests. These tests have been widely used to study changes related to negative symptoms and cognitive deficits of schizophrenia, respectively. We also evaluated changes in NeuN (a neuronal marker), Iba-1 (a microglia marker) and GFAP (an astrocyte marker) expression in the medial prefrontal cortex (mPFC), dorsal striatum, nucleus accumbens core and shell, and dorsal hippocampus by immunohistochemistry. CBD effects were compared to those induced by the atypical antipsychotic clozapine. Repeated MK-801 administration impaired performance in the social interaction and NOR tests. It also increased the number of GFAP-positive astrocytes in the mPFC and the percentage of Iba-1-positive microglia cells with a reactive phenotype in the mPFC and dorsal hippocampus without changing the number of Iba-1-positive cells. No change in the number of NeuN-positive cells was observed. Both the behavioral disruptions and the changes in expression of glial markers induced by MK-801 treatment were attenuated by repeated treatment with CBD or clozapine. These data reinforces the proposal that CBD may induce antipsychotic-like effects. Although the possible mechanism of action of these effects is still unknown, it may involve CBD anti-inflammatory and neuroprotective properties. Furthermore, our data support the view that inhibition of microglial activation may improve schizophrenia symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, both CBD and clozapine prevented the increase in the number of GFAP-positive astrocytes in the mPFC and in the percentage of Iba-1-positive microglia cells with a reactive phenotype in the dorsal hippocampus and mPFCafter repeated administration of MK-801 (71).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [71]
In the citing paper
“Confirming the involvement of limbic sites in its antipsychotic effects, CBD blocked PPI impairment induced by amphetamine after direct injection into the nucleus accumbens (71).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [71]
Citations
Cites
The mouse brain in stereotaxic coordinates
Konsman, J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 16,796
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat
Hoover, W. B., & Vertes, R. P. (2007) · Brain Structure and Function · doi:10.1007/s00429-007-0150-4 · Cited by 1,365
Jentsch, J. D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,329
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,230
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 993
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
Flagged first, then by citations
2 of the 72 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–147 of 147
Thériault, R.-K., St‐Denis, M., Hewitt, T., Khokhar, J. Y., Lalonde, J., & Perreault, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115511 · Cited by 5
Zhang, L., Zhou, Y., Xie, Y., Ying, Y., Li, Y., Ye, S., & Wang, Z. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173821 · Cited by 4
Rodrigues, F. D. S., Jantsch, J., Fraga, G. D. F., Dias, V. S., Medeiros, C. P., Wickert, F., Schröder, N., Giovernardi, M., & Guedes, R. P. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110196 · Cited by 4
da Silva, N. R., Gobbo, D., Gomes, F. V., Scheller, A., Kirchhoff, F., Bel, E. D., & Guimarães, F. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149772 · Cited by 4
Effect of cannabidiol on schizophrenia based on randomized controlled trials: A meta-analysis
Zhang, S., Li, M., & Guo, Z. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.09.019 · Cited by 5
Zuccoli, G. S., Brandão‐Teles, C., Vieira, G. M., Gomes, F. V., & Crunfli, F. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-97182-3_7 · Cited by 4
Experimental Periodontitis Worsens Dopaminergic Neuronal Degeneration
Jacob, G. A., Milan, B. A., Antonieto, L. R., Levi, Y. L. D. A. S., Ribeiro, M. C., Nassar, R. D. S. F., Sousa‐Neto, M. D., Mazzi‐Chaves, J. F., Messora, M. R., Furlaneto, F. A. C., et al. (2024) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.14065 · Cited by 3
Queiroz, S. D. A., Júnior, L. R. D. N., de Carvalho, A. B. P., da Silva, T. V., Ramos, S. D. S., Meneguzzo, V., Mathias, K., Tiscoski, A. D. B., Piacentini, N., Goldim, M. P. D. S., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.031 · Cited by 3
Sonego, A. B., Prado, D. S., Uliana, D., Cunha, T. M., Grace, A. A., & Resstel, L. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.09.001 · Cited by 5
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_465-1 · Cited by 3
Cannabidiol, cognition and schizophrenia: a narrative review
Norman, T. R. (2024) · Exploration of Medicine · doi:10.37349/emed.2024.00204 · Cited by 2
Godínez‐Chaparro, B., Rodríguez-Ramos, M. C., Martínez-Lorenzana, M. G., González-Morales, E., Pérez-Ruíz, K. P., Monteros-Zúñiga, A. E. D. L., Mendoza‐Pérez, F., & Condés‐Lara, M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173945 · Cited by 3
Lima, T. U., Zuelli, F. M. D. G. C., de Souza, A. P., Colodete, D. A. E., da Silva, N. R., Verza, F. A., Deakin, J. F. W., Del-Bel, E. A., Louzada‐Júnior, P., Del‐Ben, C. M., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.07.022 · Cited by 2
Cannabidiol and Cannabis Use Disorder
García‐Gutiérrez, M. S., Navarrete, F., Viudez‐Martínez, A., Gasparyan, A., Caparrós, E., & Manzanares, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_5 · Cited by 2
Jaehne, E. J., & van den Buuse, M. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190006 · Cited by 2
Mageed, S. S. A., Mangoura, S. A., Nassar, N. N., Moawad, H., & Kamel, A. S. E. D. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115681 · Cited by 1
Wei, Y., Liu, X., Lin, S., Jia, Z., Liu, L., Wang, B., Liao, L., & Mei, X. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05608-8 · Cited by 1
Spelta, L. E. W., Real, C. C., Bruno, V., Buchpiguel, C. A., Garcia, R. C. T., Torres, L. H., Faria, D. D. P., & Marcourakis, T. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25327 · Cited by 1
Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders
Deiana, S., & Zamberletti, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00014-8 · Cited by 1
Ma, S., Wang, X., Du, X.-Y., Su, M.-W., Yao, X., & Shi, J. (2020) · Research Square · doi:10.21203/rs.3.rs-124432/v1 · Cited by 1
Ma, S., Wang, X., & Shi, J. (2022) · Research Square · doi:10.21203/rs.3.rs-124432/v3 · Cited by 1
Neuroimagen estructural de primeros episodios psicóticos en consumidores de cánnabis
Sánchez, D. B. (2016) · Psiquiatría Biológica · doi:10.1016/j.psiq.2016.06.003
Pereira, M. D. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-24042018-181827
da Silva, N. R. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2017.tde-22082017-144713
Mecanismos envolvidos no perfil antipsicótico do canabidiol
Pedrazzi, J. F. C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2019.tde-30042019-163956
dos Santos, A. H. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-04012021-103831 · Cited by 1
Ma, S., Wang, X., & Shi, J. (2021) · Research Square · doi:10.21203/rs.3.rs-124432/v2
Modulação da atividade encefálica pelo canabidiol em camundongos tratados com cocaína
Spelta, L. E. W. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2022.tde-01122022-181624
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_465
Amaral, D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-08052023-105940
Rao, P., & Morandini, H. A. E. (2023) · Journal of Indian Association for Child and Adolescent Mental Health · doi:10.1177/09731342231179036
Psychotropic Effects of Cannabis
Ross, I. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-35155-6_6 · Cited by 3
Machado, M. M. F., Ático, E. M., Banin, R. M., Hirata, B. K. S., Kempe, P. R. G., Pedroso, A. P., Thomaz, F. M., Oyama, L. M., Ribeiro, E. B., Bueno, A. A., et al. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148659
Emerging therapeutic role of cannabis in neurological disorders
Bisht, A., Jain, S., Dwivedi, J., & Sharma, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15489-8.00005-0
Chang, C.-Y., Dai, W., & Hu, S. S. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06670-1
Canabidiol, ansiedade e memórias aversivas: uma revisão das evidências pré-clínicas
Portes, M. A. M., Werle, I., Soares, L. A., Guterres, F. D. S., & Bertoglio, L. J. (2025) · Revista Fitos · doi:10.32712/2446-4775.2025.1817
Reece, A. S., & Hulse, G. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13492-0.00002-5
Fabris, D., Andrade, L. M., Freitas, I. D. S., Gomes, F. V., & Guimarães, F. S. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.10.012
Role of the endocannabinoid system in schizophrenia: From preclinical to human evidence
Martino, S. D., Białoń, M., Drago, F., Starowicz, K., & Micale, V. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00030-x
Borges, L., Nascimento, G. C., Ferrié, L., Raisman‐Vozari, R., Figadère, B., Michel, P. P., & Bel, E. A. D. (2025) · Neurotoxicity Research · doi:10.1007/s12640-025-00772-0
Ricci, V., Sarni, A., Berardis, D. D., Martinotti, G., & Maina, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389574
Cannabidiol for the Treatment of Neurodevelopmental Disorders: Focus on Schizophrenia and Autism
Martino, S. D., Coppola, I., Drago, F., Tartaglione, A. M., & Micale, V. (2026) · Springer eBooks · doi:10.1007/978-3-032-12239-1_5
Therapeutic effect of cilastatin administration in LPS-induced retinotoxicity
Felipe, D. S., Martín‐Sánchez, B., González-Nicolás, M. Á., Llorente, R., Marco, E. M., López‐Gallardo, M., & Lázaro, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119557
Jantsch, J., Wickert, F., Fraga, G. D. F., de Fraga, L. S., Durán‐Carabali, L. E., & Guedes, R. P. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03733-x
Yoshimachi, F., Ikuta, M., Kimura, K., Wang, H., Fu, J., Kirikae, H., Kumar, A., Shima, Y., Yamamoto, Y., Miyazaki, H., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111921
Metadata
- Authors
- Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S.
- Affiliations
- Universidade de São Paulo (BR)
- Universidad Complutense de Madrid (ES)
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 164
- Issue
- 1-3
- Pages
- 155-163
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2028951205
- Cited by
- 147
- References
- 72
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 15 · 2023: 8 · 2022: 13 · 2021: 24 · 2020: 11 · 2019: 14 · 2018: 15 · 2017: 14 · 2016: 12 · 2015: 4
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Library Open Repository (Universidad Complutense Madrid) (submittedVersion)
- Funders
- FAPESP (012/17626-7)
- CNPq (470311/2012-6)
- Instituto de Salud Carlos III, Redes temáticas de Investigación Cooperativa en salud (RD2012/0028/0021)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- cannabidiol, schizophrenia
- MeSH terms
- Animals, Brain, Calcium-Binding Proteins, Cannabidiol, Clozapine, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Gene Expression Regulation, Glial Fibrillary Acidic Protein, Male, Mice, Inbred C57BL, Microfilament Proteins, Neuroglia, Phosphopyruvate Hydratase, Psychotic Disorders, Antipsychotic Agents, Dizocilpine Maleate, Excitatory Amino Acid Antagonists, Maze Learning, Recognition, Psychology, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
